DCVC Bio Announces $400M Fund Formation

Gunderson Dettmer represented client DCVC Bio in the formation of its $400 million fund, DCVC Bio III. DCVC Bio differentiates itself from other biotech­nology venture funds by investing not in specific drugs or molecules, but in scientific break­throughs by top innovators, plus computation-enhanced platforms that could generate whole new arrays of treatments or products.

In the announcement of the fund formation, the DCVC Bio team said, “At DCVC Bio, we’re excited by teams who bring all of a unique biological insight and the ability to generate enormous amounts of actionable data around that insight and the ability to deliver meaningful results more swiftly and cost-effectively. The algorithms these companies build on top of their unique insights and defensible empirical data help them more quickly find the most promising drug candidates or agri­cul­tural products, while spending less money to do it. Only after this de-risking process do they proceed to the clinic or the farm.”

The Gunderson Dettmer team was led by Steve Franklin and Chris Partin and included Mike Mattheiss and Sara Gerdes.

Companies
DCVC Bio